The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 725 N Wolfe Street, PCTB 1004, Baltimore, MD 21205, USA.
Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan, CX 1066 Amsterdam, Netherlands.
Sci Transl Med. 2021 Mar 17;13(585). doi: 10.1126/scitranslmed.abe6178.
A disintegrin and metalloprotease 10 (ADAM10) is the α-secretase for amyloid precursor protein (APP). ADAM10 cleaves APP to generate neuroprotective soluble APPα (sAPPα), which precludes the generation of Aβ, a defining feature of Alzheimer's disease (AD) pathophysiology. Reduced ADAM10 activity is implicated in AD, but the mechanisms mediating ADAM10 modulation are unclear. We find that the plasma membrane enzyme glycerophosphodiester phosphodiesterase 2 (GDE2) stimulates ADAM10 APP cleavage by shedding and inactivating reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a glycosylphosphatidylinositol (GPI)-anchored inhibitor of ADAM10. In AD, membrane-tethered RECK is highly elevated and GDE2 is abnormally sequestered inside neurons. Genetic ablation of GDE2 phenocopies increased membrane RECK in AD, which is causal for reduced sAPPα, increased Aβ, and synaptic protein loss. RECK reduction restores the balance of APP processing and rescues synaptic protein deficits. These studies identify GDE2 control of RECK surface activity as essential for ADAM10 α-secretase function and physiological APP processing. Moreover, our results suggest the involvement of the GDE2-RECK-ADAM10 pathway in AD pathophysiology and highlight RECK as a potential target for therapeutic development.
一种解整合素金属蛋白酶 10(ADAM10)是淀粉样前体蛋白(APP)的α-分泌酶。ADAM10 切割 APP 生成具有神经保护作用的可溶性 APPα(sAPPα),从而阻止了阿尔茨海默病(AD)病理生理学中标志性的 Aβ的生成。AD 中 ADAM10 活性降低与其相关,但介导 ADAM10 调节的机制尚不清楚。我们发现,质膜酶甘油磷酸二酯磷酸二酯酶 2(GDE2)通过脱落和使富含半胱氨酸的 Kazal 基序的反转诱导型胱天蛋白酶抑制剂(RECK)失活来刺激 ADAM10 APP 切割,RECK 是 ADAM10 的糖基磷脂酰肌醇(GPI)锚定抑制剂。在 AD 中,膜结合的 RECK 高度升高,GDE2 异常地被隔离在神经元内。GDE2 的基因缺失模拟了 AD 中膜结合 RECK 的增加,这导致 sAPPα 减少、Aβ 增加和突触蛋白丢失。RECK 减少恢复了 APP 加工的平衡并挽救了突触蛋白的不足。这些研究确定了 GDE2 对 RECK 表面活性的控制是 ADAM10 α-分泌酶功能和生理 APP 加工所必需的。此外,我们的结果表明,GDE2-RECK-ADAM10 途径参与了 AD 的病理生理学,并强调了 RECK 作为治疗开发的潜在靶点。